Atea Pharmaceuticals Inc. (AVIR): Price and Financial Metrics
GET POWR RATINGS... FREE!
AVIR Stock Price Chart Interactive Chart >
AVIR Price/Volume Stats
| Current price | $23.58 | 52-week high | $94.17 |
| Prev. close | $23.81 | 52-week low | $18.72 |
| Day low | $22.74 | Volume | 1,556,722 |
| Day high | $23.84 | Avg. volume | 610,640 |
| 50-day MA | $30.34 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 1.95B |
Atea Pharmaceuticals Inc. (AVIR) Company Bio
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
Latest AVIR News From Around the Web
Below are the latest news stories about Atea Pharmaceuticals Inc that investors may wish to consider to help them evaluate AVIR as an investment opportunity.
Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare ConferenceBOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman and Chief Executive Officer of Atea will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:30 p.m. ET. A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation. About Atea Pharmaceuticals Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializin... |
Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC (Revised)Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications. |
Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of DirectorsFormer U.S. Surgeon General Brings Wealth of Clinical and Public Health ExperienceBOSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Directors. Dr. Adams most recently served as Surgeon General of the United States and brings a wide range of experience spanning clinical practice, clinical research, public health, and government agency leadership. “We are honored to welcome Dr. Adams to our Board of Directors, as his unique experience as Surgeon General during the COVID-19 pandemic will undoubtedly help guide Atea as we continue to advance our antiviral pipeline, i... |
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics DebutsHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Novo Nordisk A/S (NYSE: NVO ) Vaccitech plc (NASDAQ: VACC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 13) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) ADC Therapeutics SA (NYSE: ADCT ) Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) Achilles Therapeutics plc (NASDAQ: ACHL ) Akouos, Inc. (NASDAQ: AKUS ) (announced its first-quarter results) Applied Genetic Technologies Corporation (NASDAQ: AGTC ) Aprea Therapeutics, Inc. (NASDAQ: APRE ) Aquestive Therapeutics, Inc. (NASDAQ: AQST ) Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) Atreca, ... |
Atea Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobal Phase 3 MORNINGSKY trial of AT-527 in the outpatient setting recently initiated for the treatment of COVID-19Enrollment advancing in Phase 1a trial of AT-752; drug candidate being developed for the treatment of dengue fever BOSTON, May 13, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the quarter ended March 31, 2021 and provided a corporate update. “Over the course of a year, we have gone from filing an Investigational New Drug Application for AT-527, an oral direct-acting antiviral for the treatment of COVID-19, to the recent initiation of a global Phase 3 trial in the outpatient setting. Working closely with our strategic partner Roche, this significant milestone rep... |
AVIR Price Returns
| 1-mo | 2.92% |
| 3-mo | -69.54% |
| 6-mo | -24.28% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -43.56% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...